Genprex, Inc. Stock

$0.31

11.30% today

Nasdaq, Jul 14, 09:18 pm CET

ISIN

US3724461047

Symbol

GNPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Genprex, Inc. Stock price

$0.28

-115.72 99.76% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.01 4.81%

ISIN

US3724461047

Symbol

GNPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$9.2m

Enterprise Value

$5.7m

Net debt

positive

Cash

$3.5m

Shares outstanding

24.2m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.4

Financial Health

Equity Ratio

39.3%

Return on Equity

-1,320.1%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | -

EBIT

- | $-24.7m

Net Income

- | $-30.8m

Free Cash Flow

$-16.0m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Genprex, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Genprex, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Genprex, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Genprex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	21% 21% -
- Research and Development Expense	11 11	40% 40% -
EBITDA	-21 -21	32% 32% -
- Depreciation and Amortization	0.01 0.01	0% 0% -
EBIT (Operating Income) EBIT	-21 -21	32% 32% -
Net Profit	-21 -21	31% 31% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Genprex, Inc. Stock News

Neutral

PRNewsWire

●

20 days ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive precl...

Neutral

PRNewsWire

●

21 days ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System AUSTIN, Texas , June 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical ...

Neutral

PRNewsWire

●

about one month ago

Genprex to Participate at BIO 2025 International Convention

AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance fr...

More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office	United States
CEO	Ryan Confer
Employees	15
Founded	2009
Website	www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now